DE2515001C2 - Prostaglandin enthaltende gefriergetrocknete Pulver - Google Patents
Prostaglandin enthaltende gefriergetrocknete PulverInfo
- Publication number
- DE2515001C2 DE2515001C2 DE2515001A DE2515001A DE2515001C2 DE 2515001 C2 DE2515001 C2 DE 2515001C2 DE 2515001 A DE2515001 A DE 2515001A DE 2515001 A DE2515001 A DE 2515001A DE 2515001 C2 DE2515001 C2 DE 2515001C2
- Authority
- DE
- Germany
- Prior art keywords
- freeze
- prostaglandin
- tris
- dried
- hydroxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims description 41
- 239000000843 powder Substances 0.000 title claims description 16
- 239000000243 solution Substances 0.000 claims description 19
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 18
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229960002986 dinoprostone Drugs 0.000 description 9
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003262 carboxylic acid ester group Chemical class [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 hydroxy fatty acids Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 238000010327 methods by industry Methods 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2515001A DE2515001C2 (de) | 1975-04-04 | 1975-04-04 | Prostaglandin enthaltende gefriergetrocknete Pulver |
| US05/669,336 US4058623A (en) | 1975-04-04 | 1976-03-22 | Prostaglandin-containing lyophilized powders |
| NLAANVRAGE7603043,A NL183439C (nl) | 1975-04-04 | 1976-03-23 | Werkwijze voor de bereiding van een prostaglandine-bevattend gevriesdroogd poeder dat tevens polyvinylpyrrolidon bevat, alsmede werkwijze voor de bereiding van een geneesmiddel met prostaglandine-werking. |
| FI760800A FI59022C (fi) | 1975-04-04 | 1976-03-25 | Foerfarande foer framstaellning av prostaglandin e2 eller dess derivat innehaollande frystorkat pulver |
| DK131976A DK146435C (da) | 1975-04-04 | 1976-03-25 | Fremgangsmaade til fremstilling af stabilt prostaglandinholdigt, frysetoerret pulver |
| SE7603741A SE427006B (sv) | 1975-04-04 | 1976-03-29 | Sett att framstella frystorkat pulver innehallande prostaglandin |
| CH396276A CH637375A5 (de) | 1975-04-04 | 1976-03-30 | Verfahren zur herstellung von tris(hydroxymethyl)-aminomethan-salzen von prostansaeuren. |
| IE701/76A IE42671B1 (en) | 1975-04-04 | 1976-04-02 | Prostaglandin containing compositions |
| FR7609599A FR2305972A1 (fr) | 1975-04-04 | 1976-04-02 | Poudres lyophilisees contenant des prostaglandines |
| BE165827A BE840357A (fr) | 1975-04-04 | 1976-04-02 | Poudre lyophilisee contenant de la prostaglandine, son procede de preparation et son utilisation |
| LU74695A LU74695A1 (cg-RX-API-DMAC7.html) | 1975-04-04 | 1976-04-02 | |
| JP51038124A JPS5940147B2 (ja) | 1975-04-04 | 1976-04-05 | プロスタグランジン含有凍結乾燥粉末、その製法及び医薬及び獣医薬組成物 |
| GB13689/76A GB1540483A (en) | 1975-04-04 | 1976-04-05 | Prostaglandin containing compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2515001A DE2515001C2 (de) | 1975-04-04 | 1975-04-04 | Prostaglandin enthaltende gefriergetrocknete Pulver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2515001A1 DE2515001A1 (de) | 1976-10-14 |
| DE2515001C2 true DE2515001C2 (de) | 1986-10-02 |
Family
ID=5943206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2515001A Expired DE2515001C2 (de) | 1975-04-04 | 1975-04-04 | Prostaglandin enthaltende gefriergetrocknete Pulver |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4058623A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS5940147B2 (cg-RX-API-DMAC7.html) |
| BE (1) | BE840357A (cg-RX-API-DMAC7.html) |
| CH (1) | CH637375A5 (cg-RX-API-DMAC7.html) |
| DE (1) | DE2515001C2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK146435C (cg-RX-API-DMAC7.html) |
| FI (1) | FI59022C (cg-RX-API-DMAC7.html) |
| FR (1) | FR2305972A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1540483A (cg-RX-API-DMAC7.html) |
| IE (1) | IE42671B1 (cg-RX-API-DMAC7.html) |
| LU (1) | LU74695A1 (cg-RX-API-DMAC7.html) |
| NL (1) | NL183439C (cg-RX-API-DMAC7.html) |
| SE (1) | SE427006B (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA787353B (en) * | 1978-05-17 | 1980-08-27 | Wellcome Found | Pharmaceutical formulations |
| US4301146A (en) * | 1980-07-29 | 1981-11-17 | G. D. Searle & Co. | Stabilization of 16-oxygenated prostanoic acid derivatives |
| DE3162914D1 (en) * | 1981-01-10 | 1984-05-10 | Chinoin Gyogyszer Es Vegyeszet | Stabilized prostaglandin tablets for topical use with regulated dissolving speed and process for preparing them |
| US4675182A (en) * | 1983-02-12 | 1987-06-23 | Bayer Aktiengesellschaft | Complexes of prostaglandins |
| US4835320A (en) * | 1986-06-03 | 1989-05-30 | Societe Francaise Hoechst | Process for the preparation of glyoxal monoactals |
| US4857711A (en) * | 1988-08-16 | 1989-08-15 | Illinois Tool Works Inc. | Positive temperature coefficient heater |
| JPH02149353U (cg-RX-API-DMAC7.html) * | 1989-05-22 | 1990-12-19 | ||
| JPH03107251U (cg-RX-API-DMAC7.html) * | 1989-06-30 | 1991-11-05 | ||
| DE4125255A1 (de) * | 1991-07-31 | 1993-02-04 | Knoll Ag | Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung |
| CA2222811C (en) * | 1995-06-01 | 2008-09-30 | G.D. Searle & Co. | Stabilized solid dispersions of misoprostol |
| AU4218400A (en) * | 1999-04-05 | 2000-10-23 | Emisphere Technologies, Inc. | Lyophilized solid dosage forms and methods of making |
| US20090035260A1 (en) * | 2002-07-29 | 2009-02-05 | Therapicon Srl | Enhanced nasal composition of active peptide |
| ITMI20040235A1 (it) * | 2004-02-13 | 2004-05-13 | Therapicon Srl | Preparazione farmaceutica per il cavo orale |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3069322A (en) * | 1958-05-28 | 1962-12-18 | Bergstrom Sune | Pge and pgf |
| US3644638A (en) * | 1970-08-24 | 1972-02-22 | American Home Prod | Compositions and methods for relieving bronchial spasm with prostanoic acids and esters |
| FR2157899A1 (en) * | 1971-10-22 | 1973-06-08 | Upjohn Co | 16-mono and di-lower alkyl prostaglandin compsns - - for treatment of peptic ulcers |
| US3904679A (en) * | 1972-05-23 | 1975-09-09 | Upjohn Co | 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs |
| US3826823A (en) * | 1972-09-25 | 1974-07-30 | Syntex Inc | Stabilized prostaglandin preparations |
| US3954787A (en) * | 1974-06-18 | 1976-05-04 | Pfizer Inc. | Stabilized E-series prostaglandins |
-
1975
- 1975-04-04 DE DE2515001A patent/DE2515001C2/de not_active Expired
-
1976
- 1976-03-22 US US05/669,336 patent/US4058623A/en not_active Expired - Lifetime
- 1976-03-23 NL NLAANVRAGE7603043,A patent/NL183439C/xx not_active IP Right Cessation
- 1976-03-25 FI FI760800A patent/FI59022C/fi not_active IP Right Cessation
- 1976-03-25 DK DK131976A patent/DK146435C/da not_active IP Right Cessation
- 1976-03-29 SE SE7603741A patent/SE427006B/xx not_active IP Right Cessation
- 1976-03-30 CH CH396276A patent/CH637375A5/de not_active IP Right Cessation
- 1976-04-02 FR FR7609599A patent/FR2305972A1/fr active Granted
- 1976-04-02 LU LU74695A patent/LU74695A1/xx unknown
- 1976-04-02 IE IE701/76A patent/IE42671B1/en unknown
- 1976-04-02 BE BE165827A patent/BE840357A/xx not_active IP Right Cessation
- 1976-04-05 GB GB13689/76A patent/GB1540483A/en not_active Expired
- 1976-04-05 JP JP51038124A patent/JPS5940147B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IE42671B1 (en) | 1980-09-24 |
| NL7603043A (nl) | 1976-10-06 |
| SE427006B (sv) | 1983-02-28 |
| CH637375A5 (de) | 1983-07-29 |
| NL183439C (nl) | 1988-11-01 |
| SE7603741L (sv) | 1976-10-05 |
| FI760800A7 (cg-RX-API-DMAC7.html) | 1976-10-05 |
| GB1540483A (en) | 1979-02-14 |
| FR2305972B1 (cg-RX-API-DMAC7.html) | 1979-09-21 |
| DE2515001A1 (de) | 1976-10-14 |
| JPS5940147B2 (ja) | 1984-09-28 |
| JPS51127048A (en) | 1976-11-05 |
| BE840357A (fr) | 1976-10-04 |
| FI59022B (fi) | 1981-02-27 |
| DK131976A (da) | 1976-10-05 |
| LU74695A1 (cg-RX-API-DMAC7.html) | 1976-11-11 |
| IE42671L (en) | 1976-10-04 |
| FI59022C (fi) | 1981-06-10 |
| US4058623A (en) | 1977-11-15 |
| DK146435C (da) | 1984-03-26 |
| FR2305972A1 (fr) | 1976-10-29 |
| NL183439B (nl) | 1988-06-01 |
| DK146435B (da) | 1983-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69223624T2 (de) | Taxan-derivate enthaltende arzneimittel | |
| DE69102307T2 (de) | Omeprazolezusammensetzung zur rektalen Anwendung. | |
| DE2515001C2 (de) | Prostaglandin enthaltende gefriergetrocknete Pulver | |
| DE69109021T2 (de) | Augentropfenarzneimittel. | |
| DE3346123A1 (de) | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung | |
| EP0806955B1 (de) | Enrofloxacin-injektions- oder infusionslösungen | |
| EP0240484A1 (de) | Pharmazeutische Zubereitung sowie Verfahren zur Herstellung derselben | |
| DE10334820B4 (de) | Pharmazeutische Zusammensetzungen mit antibiotischer Aktivität | |
| DE2323187C2 (de) | Verfahren zur Herstellung einer stabilisierten, pulverförmigen Secretinzubereitung | |
| DE69904727T2 (de) | Injizierbares arzneimittel auf basis eines pharmazeutisch verträglichen salzes von clopidogrel bzw. von ticlopidin | |
| DE3923270A1 (de) | Wasserloesliche pharmazeutische metallocen-komplex-zusammensetzung | |
| DE2920020C2 (cg-RX-API-DMAC7.html) | ||
| EP0143857B1 (de) | Coronartherapeutikum in Form von Weichgelatine-Kapseln | |
| DE2353797A1 (de) | Stabilisierung von prostaglandinen | |
| DE69808793T2 (de) | Pharmazeutische zusammensetzungen aus dalfopristine und quinupristine und verfahren zu ihrer herstellung | |
| DE19529057A1 (de) | Ifosfamid-Lyophilisat-Zubereitungen | |
| EP0679395A1 (de) | Pharmazeutische Zubereitungen aud der Basis einer Ketoprofenlösung in weichen Gelatinekapseln und Verfahren zu deren Herstellung | |
| EP0021184B1 (de) | Sekretinpräparate mit verstärkter und protrahierter Wirkung, Verfahren zu ihrer Herstellung sowie Dihydroxybenzoyl-L-tyrosin | |
| DE2719690A1 (de) | Stabilisierte prostaglandinzubereitung und verfahren zur herstellung derselben | |
| DE2719581A1 (de) | Polyhydroxyphenylchromanone enthaltende arzneimittel | |
| EP0116358B1 (de) | Komplexe von Prostaglandinen | |
| DE3142853A1 (de) | Feste arzneizubereitungen mit nifedipin und verfahren zu ihrer herstellung | |
| DE2243776A1 (de) | Komplexe von tetracyclinen mit tris(hydroxymethyl)-aminomethan | |
| DE4010536A1 (de) | Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure | |
| AT401469B (de) | Pharmazeutische wässrige lösung zur parenteralen anwendung enthaltend einen in situ gebildeten komplex von einem alkaloid mit bis-indol-gerüst, sowie verfahren zu deren herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |